A LEGISLATIVE HEARING TO EXAMINE A DISCUSSION DRAFT, S.__, THE TOXIC SUBSTANCES CONTROL ACT FEE REAUTHORIZATION AND IMPROVEMENT ACT OF 2026

Senate Public Works Committee Senate March 4, 2026

Official record ↗ · Linked to the scheduled hearing

Full text of the official published hearing record. Extracted from the source document — verify against the official record for citation.

[Senate Hearing 119-406]
[From the U.S. Government Publishing Office]

 S. Hrg. 119-406

 A LEGISLATIVE HEARING TO EXAMINE A DISCUS-
 SION DRAFT, S.__, THE TOXIC SUBSTANCES 
 CONTROL ACT FEE REAUTHORIZATION AND 
 IMPROVEMENT ACT OF 2026
=======================================================================

 HEARING

 BEFORE THE

 COMMITTEE ON
 ENVIRONMENT AND PUBLIC WORKS

 UNITED STATES SENATE

 ONE HUNDRED NINETEENTH CONGRESS

 SECOND SESSION

 __________

 MARCH 4, 2026

 __________

 Printed for the use of the Committee on Environment and Public Works
 
[GRAPHIC NOT AVAILABLE IN TIFF FORMAT] 

 Available via the World Wide Web: http://www.govinfo.gov
 __________
 
 U.S. GOVERNMENT PUBLISHING OFFICE
63-733 WASHINGTON : 2026
======================================================================= 
 
 COMMITTEE ON ENVIRONMENT AND PUBLIC WORKS

 ONE HUNDRED NINETEENTH CONGRESS

 SECOND SESSION

 SHELLEY MOORE CAPITO, West Virginia, Chairman
 SHELDON WHITEHOUSE, Rhode Island, Ranking Member

KEVIN CRAMER, North Dakota BERNARD SANDERS, Vermont
CYNTHIA M. LUMMIS, Wyoming JEFF MERKLEY, Oregon
JOHN R. CURTIS, Utah EDWARD J. MARKEY, Massachusetts
LINDSEY O. GRAHAM, South Carolina MARK KELLY, Arizona
DAN SULLIVAN, Alaska ALEX PADILLA, California
PETE RICKETTS, Nebraska ADAM B. SCHIFF, California
ROGER F. WICKER, Mississippi LISA BLUNT ROCHESTER, Delaware
JOHN BOOZMAN, Arkansas ANGELA D. ALSOBROOKS, Maryland
JON HUSTED, Ohio

 Adam Tomlinson, Republican Staff Director
 Dan Dudis, Democratic Staff Director
 
 C O N T E N T S

 ---------- 
 Page

 MARCH 4, 2026
 OPENING STATEMENTS

Cramer, Hon. Kevin, U.S. Senator from the State of North Dakota.. 1
Whitehouse, Hon. Sheldon, U.S. Senator from the State of Rhode 
 Island......................................................... 3

 WITNESSES

Engler, Richard, PH.D., Director of Chemistry, Berguson & 
 Campbell, on behalf of the Coalition for Chemical Innovation... 4
 Prepared statement........................................... 7
 Responses to additional questions from:
 Senator Capito........................................... 26
 Senator Lummis........................................... 38
 Senator Curtis........................................... 44
 Senator Padilla.......................................... 47
Isaacs, David, Vice President, Government Affairs, Semiconductor 
 Industry Association........................................... 51
 Prepared statement........................................... 53
 Responses to additional questions from:
 Senator Lummis........................................... 65
 Senator Kelly............................................ 66
 Senator Padilla.......................................... 70
Freedhoff, Michael, PH.D., Senior Policy Advisor, Holland & 
 Knight, LLP.................................................... 71
 Prepared statement........................................... 73
 Responses to additional questions from:
 Senator Capito........................................... 90
 Senator Padilla.......................................... 98
 Senator Blunt Rochester.................................. 99

 ADDITIONAL MATERIAL

New York Times Article: She Fought for a Carcinogen. Now She is 
 at the E.P.A., Approving New Chemicals......................... 112
Letter to Senator Capito, Senator Whitehouse, Senator Curtis, and 
 Senator Merkley from:
 dsm-firmenich................................................ 129
 Household Commercial Products Association.................... 131
Letter to Senator Capito, Senator Whitehouse, Senator Guthrie, 
 and Senator Pallone from American Alliance for Innovation 133
Letter to Senator Capito and Senator Whitehouse from:
 American Chemistry Council................................... 138
 American Petroleum Institute................................. 140
 National Association of Manufacturers........................ 142
 Physicians Committee for Responsible Medicine................ 145

 
 A LEGISLATIVE HEARING TO EXAMINE A DISCUSSION DRAFT, S.__,
 THE TOXIC SUBSTANCES CONTROL ACT FEE REAUTHORIZATION AND IMPROVEMENT 
 ACT OF 2026

 ---------- 

 WEDNESDAY, MARCH 4, 2026

 U.S. Senate,
 Committee on Environment and Public Works,
 Washington, DC.
 The committee met, pursuant to notice, at 10:09 a.m. in 
room 562, Dirksen Senate Office Building, Hon. Kevin Cramer 
(chairman of the committee) presiding.
 Present: Senators Cramer, Whitehouse, Ricketts, Boozman, 
Merkley, Markey, Padilla, Blunt Rochester, Alsobrooks.

 OPENING STATEMENT OF HON. KEVIN CRAMER, 
 U.S. SENATOR FROM THE STATE OF NORTH DAKOTA

 Senator Cramer. Good morning, and thank you all for being 
here today.
 This morning, we will receive testimony on a legislative 
discussion draft entitled The Toxic Substances Control Act Fee 
Reauthorization and Improvement Act of 2026. This discussion 
draft would make targeted reforms to the Toxic Substances 
Control Act, or TSCA, with a straightforward goal: to improve 
the Environmental Protection Agency's New Chemical Review 
process.
 Congress set a clear standard and TSCA was signed into law 
50 years ago. The EPA was to carry out the law in a reasonable 
and prudent manner, taking into account environmental, economic 
and social impacts. That was the right standard then, it 
remains the right standard today, to guide our efforts to 
improve and implement these processes.
 When Congress last amended TSCA 10 years ago, we sought to 
modernize the statute to reflect current needs and technology. 
Unfortunately, the EPA's implementation of it is New Chemicals 
Program has drifted from Congress' original mandate. In 
practice today, it is neither reasonable nor prudent, and 
ignores environmental, economic and social impacts from a 
prolonged and uncertain process.
 In the case when the EPA does approve new, often innovative 
and safer chemistries, the agency imposes costly, burdensome or 
even unnecessary restrictions. In one case, a company 
manufacturing a new chemical wanted to pursue a zero waste 
initiative to recycle all of it is wastewater. By any measure, 
that is a better environmental outcome.
 The EPA rejected that approach, not because it was unsafe, 
but because it did not fit the agency's one-size-fits-all 
rules. Rather than recycle it is waste, that company was forced 
to burn water to comply with EPA's requirements. That is 
neither reasonable nor prudent.
 The consequences are real. They are moving us in the wrong 
direction. Companies delay or abandon developing safer 
alternative in America, while shifting investment and 
production overseas to places like Europe and China. One 
company now labels it is newest innovations as non-TSCA, 
meaning they are developed for every market in the world except 
the United States. This harms our economic competitiveness, and 
it eliminates American jobs.
 The outcomes are the predictable result of a program that 
is no longer functioning in the manner Congress directed, or 
mindful of real-world consequences. This problem also impacts 
our national security. Throughout our government and across our 
Country, there are coordinated efforts to rebuild domestic 
semiconductor manufacturing, semiconductors that are required 
for current and future defense systems. These facilities rely 
on the use of specialty chemicals, subject to the EPA's New 
Chemical Review process.
 The semiconductor industry reports that bringing a new 
single new chip-making chemical to market in the United States 
can require up to 15 years of testing, and millions of dollars. 
By the time a company recoups that testing investment, the 
industry has already moved on to newer chemicals.
 These are extremely low-volume chemistries, used in tightly 
controlled clean rooms, which is exactly why Europe and Asia do 
not require this level of testing, and grant approvals in under 
3 months.
 The EPA's onerous requirements simply mean that leading 
edge materials are not sent to the United States market. The 
most advanced manufacturing facilities in the world, facilities 
that are critical to protect our Country, need access to small 
quantities of highly specialized chemistries to operate. An 
inefficient review process is a challenging obstacle to 
overcome.
 The 2016 TSCA amendments prioritized policies that 
addressed existing chemicals. When a statutory program is up 
for reauthorization, Congress has an opportunity to review and 
address problems in the law and it is implementation. Ten years 
later, it is clear the New Chemical program needs the same 
attention.
 This discussion draft makes targeted reforms to TSCA 
designed to do so. The draft recognizes that a one-size-fits-
all review model does not reflect reality and instead 
prioritizes flexibility and predictability. It would establish 
review periods to match the complexity and risk profile of each 
submission. Separate pathways are rerated so novel or higher 
risk substances are carefully scrutinized, while familiar 
chemistries with established data can be approved more quickly.
 It requires EPA to articulate clear expectations from the 
start, asks manufacturers to meet a higher standard up front, 
and provides predictable timelines when they do. The draft 
recognizes that EPA requires sufficient resources to 
efficiently fulfill its statutory obligations and reauthorizes 
a user fee for new chemical applicants to support the EPA's 
program.
 Taken together, the policies in the discussion draft build 
a system that protects public health, incentivizes innovation, 
and benefits the environment by giving the EPA the resources, 
the structure, and the direction to do its job well.
 This discussion draft is the starting point for our 
legislative process. I look forward to working with Ranking 
Member Whitehouse and all the members of the committee to 
develop strong, bipartisan and durable legislation.
 Ranking Member Whitehouse, I now recognize you for your 
opening statement.

 OPENING STATEMENT OF HON. SHELDON WHITEHOUSE, 
 U.S. SENATOR FROM THE STATE OF RHODE ISLAND

 Senator Whitehouse. Thank you, Chair Cramer, and thank you 
to our witnesses. A particular thank you to Chairman Capito and 
her team for convening us here today to discuss improving the 
Toxic Substances Control Act, and for ongoing bipartisan 
conversation on further improvements.
 There will be differing views on what it means to improve 
this law. Chair Capito has released her own discussion draft. 
While I do not much like many of its components, I do 
appreciate Chair Capito's willingness to engage with Democrats 
and listen to our perspectives during today's hearing. I am 
hopeful that we can find common purpose to make the law more 
effective while also more protective of public health.
 The 2016 Lautenberg Chemical Safety Act was a historic 
achievement. Working together, we strengthened TSCA to better 
deliver on the law's fundamental purpose, to protect the 
public. I am proud to have played a role in those negotiations.
 That law established a fee to improve program 
administration. It funds 25 percent of the EPA's New Chemicals 
Review program. It will sunset September 30th. Loss of these 
fees will substantially curtail the EPA's ability to conduct 
independent analyses focused on protecting public health and 
the environment.
 A simple reauthorization of the fees provision remains a 
path forward. I am interested in discussing what if any room 
there is for agreement on further improvements to the program. 
When it comes to chemical safety, the biggest challenge we face 
is the corporate capture of the EPA since January 2025. The EPA 
has long faced funding and staffing challenges that have 
impeded it from fully executing its statutory mission, but now 
things are even worse. High ranking operatives of the chemical 
industry run the Chemicals office.
 Innovation and the global competitiveness of American 
business is important. However, unregulated industry has not 
proven to be a trustworthy steward either of public or 
environmental health. The fossil fuel, tobacco and 
pharmaceutical industries demonstrate time and again that 
profits matter more to them than truth or the public interest.
 The chemical sector in America has yet to prove itself any 
better. During a Chemical Subcommittee hearing last October, we 
heard how PFAS manufacturers knew about the risks their product 
posed to human health, and yet suppressed this information for 
decades. If we are going to pursue a conversation about TSCA, 
we need to put safeguards into place so that industry 
perspectives are not determinative of regulatory outcomes.
 Closely related to concerns about corporate capture is 
concern about scientific integrity. The Trump administration 
has consistently demonstrated a willingness to deform the 
definition of best available science. The so-called Gold 
Standard Science Executive Order gives agency appointees 
beholden to Trump's industry donors, not scientists with 
objective expertise, authority to correct scientific 
information.
 That is not science. That is Zeldin's political team 
finding the industry-friendly outcome they want, and then 
looking for reasons, real or fabricated, to justify that 
outcome.
 Real science entails replicable, iterative methods for 
answering questions. These methods are not new. They are well-
established. They have existed for centuries. Those best 
positioned to carry out these methods are scientists who have 
been properly trained and who do not have financial conflicts 
of interest. We have, in this committee, an obligation to 
protect science and the scientists from political interference.
 I want to acknowledge the effort put into developing the 
discussion draft. It grapples with some of the concerns 
presented during our hearings. I appreciate the provisions 
addressing peer review, protecting bipartisan EPA programs, and 
clarifying data requirements to cut down the back and forth 
between the EPA and industry applicants.
 I have serious concerns with other provisions, such as 
those that may remove dangerous chemicals from EPA review, 
circumvent proper scientific review, or reflect deference to 
industry without adequate protection for public health and the 
environment.
 I look forward to continuing to explore, if there is a 
package of real improvements, changes that improve public 
health that we can report out of this committee. If not, I am 
ready to report a simple fee reauthorization.
 Thank you very much, Chairman.
 Senator Cramer. Thank you, Ranking Member Whitehouse.
 We will now turn to our witnesses for their opening 
statements. Thank you all for being here.
 Our first witness is Dr. Richard Engler, the Director of 
Chemistry for Berguson and Campbell. He is testifying this 
morning on behalf of the Coalition for Chemical Innovation. Dr. 
Engler has 17 years of experience at the EPA and over 25 years 
of experience implementing and engaging with the agency's TSCA 
program.
 Welcome, Dr. Engler. You are recognized for 5 minutes for 
your opening statement.

 STATEMENT OF RICHARD ENGLER, PH.D., DIRECTOR OF CHEMISTRY, 
BERGUSON AND CAMPBELL, ON BEHALF OF THE COALITION FOR CHEMICAL 
 INNOVATION

 Mr. Engler. Thank you very much.
 Good morning, Chairman Cramer, Ranking Member Whitehouse, 
Chairman Curtis, Ranking Member Merkley, and members of the 
committee. Thank you for inviting me to testify about TSCA and 
opportunities for its improvement.
 As you have heard, I have extensive experience with TSCA, 
premanufacture notices and low volume exemptions, PMNs and 
LVEs. I speak today on behalf of the Coalition for Chemical 
Innovation, CCI, a group that advocates for improvements to the 
TSCA New Chemicals program.
 In the decades since Congress amended TSCA, EPA has 
reviewed thousands of new chemicals, including PMNs and LVEs, a 
noteworthy achievement. Much has been said about review delays. 
Delays arise for various reasons, including poor submissions, 
EPA resource limits, EPA errors and EPA interpretation of key 
terms in TSCA.
 Contrary to what we have heard in other hearings, in our 
experience, delays are primarily not due to the lack of data. 
More and better data on new chemicals is not the magic bullet 
answer.
 Part of the problem is statutory ambiguities. In 
particular, the terms ``may present an unreasonable risk,'' and 
``intended, known, and reasonably foreseen circumstances.'' 
Despite our advocacy about the meaning of reasonably foreseen, 
EPA has been resolute in finding that the vast majority of new 
chemicals may present an unreasonable risk and restricting 
them.
 Only if EPA finds that a substance has low hazard for 
health and the environment, so-called low-low cases, will EPA 
forego a restriction. Let me be clear: there is no way to test 
out of a restriction unless the testing shows low hazard.
 In 2016, Congress considered and rejected an even more 
protective standard for TSCA, reasonable likelihood of no harm. 
Yet that is essentially what EPA has done across four 
administrations now. While it may seem intuitive to want all 
hazards addressed by a restriction, that is neither desirable 
nor good Federal policy. Not all hazards present actual risk, 
and as a society, we do not insist on or benefit from this 
level of risk mitigation.
 In my testimony before the House in 2025, I used a shark 
and swimmer analogy to explain the difference between hazard 
and risk. A shark in the ocean is a hazard to swimmers. It is 
not a risk if the shark is not near the swimmer.
 Staying with that analogy, EPA's approach to new chemicals 
assumes that because sharks and swimmers are both in the ocean, 
swimming in the ocean may present an unreasonable risk. EPA 
then imposes a requirement that every beach owner provide shark 
cages for all swimmers, require each swimmer to use a cage, and 
keep records documenting that fact. If the owner does not have 
records, the owner faces fines and reputational harm, even if 
they did provide cages, and whether or not there was a shark 
nearby.
 You can also imaging that a swimmer might be reluctant to 
go to that beach that requires the shark cages. Why deal with 
the hassle of using a cage and the implication of higher risk 
when you can just swim in a lake or a pool?
 EPA is saying that eventually swimmers will get over it. 
After all, EPA is letting you swim in the ocean. What is the 
problem? Regulations have cost and add economic friction. 
Sometimes shark cages are justified, but many times they are 
not.
 We are not talking about PFAS, with shorter chains that may 
still pose an unreasonable risk, the equivalent of replacing a 
megalodon with a great white shark. Without certainty of no 
risk, EPA is requiring shark cages for nearly every PMN, even 
for bio-based, biodegradable products among the lowest in its 
class, low enough to be included on EPA's Safer Choice list of 
safer ingredients, but still not low-low. Only when EPA finds 
that a shark cannot bite a person, those rare low-low cases, is 
EPA foregoing the cages.
 Consider another example. If chemical burns are an 
unreasonable risk, as EPA states that they are, one could argue 
that thermal burns are as well. Nothing in TSCA differentiates 
the two. That means that EPA must issue a restriction for 
substances that can get hot and cause burns. Nothing in the 
statute precludes EPA from doing so, and given EPA's view on 
chemical burns, to be consistent EPA must issue a restriction 
protecting against thermal burns. After all, a burn is a burn.
 If EPA were to review steel under TSCA, EPA would have to 
conclude that the substance presents an unreasonable risk when 
hot because someone might get burned and would prohibit use in 
ovens, forcing the use of more expensive, non-heat conducting 
material. Is it not reasonable to think that a person will 
protect themselves from a hot oven?
 It makes sense for EPA to use TSCA to protect against an 
invisible hazard, such as systemic, developmental, and 
reproductive toxicity. I do not think TSCA authority is needed 
to protect against common, everyday hazards, including 
irritation, corrosion, flammability, and inert dust. It is not 
that these hazards do not require protection, it is that they 
are everyday hazards common across thousands of chemicals that 
reasonable people can and do routinely manage and are managed 
by other authorities.
 Congress must act to clarify key statutory terms, including 
what is an unreasonable risk, and the boundaries of what is 
reasonably foreseen. Otherwise, EPA will continue to keep 
excellent sustainable products from adoption in the U.S. Our 
health, our environment and our economy will be poorer for it.
 Thank you again for this opportunity.
 [The prepared statement of Mr. Engler follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] 
 
 Senator Cramer. Thank you, Dr. Engler.
 Next we will hear from David Isaacs, the Vice President of 
Intergovernmental Affairs for the Semiconductor Industry 
Association. Mr. Isaacs represents one of the most critical 
industries for American innovation and national security, and 
will discuss how TSCA implementation can prevent the U.S. 
semiconductor industry from competing globally.
 Mr. Isaacs, welcome, and we look forward to your testimony.

STATEMENT OF DAVID ISAACS, VICE PRESIDENT, GOVERNMENT AFFAIRS, 
 SEMICONDUCTOR INDUSTRY ASSOCIATION

 Mr. Isaacs. Thank you, Chairman Cramer, Ranking Member 
Whitehouse, and members of the committee. My name is David 
Isaacs, testifying on behalf of the Semiconductor Industry 
Association.
 I think the committee members know the importance of the 
U.S. semiconductor industry to our economy, our technology 
leadership and our national security. That is because chips are 
the fundamental enabling technology behind the artificial 
intelligence revolution and innovation in sectors across the 
economy, from telecom to healthcare and energy and 
transportation and manufacturing and others.
 Fortunately, our industry is experiencing significant 
growth here in the U.S., with $640 billion announced in recent 
years in new investments in all parts of the supply chain in 
projects around the Country.
 Semiconductor manufacturing is a highly complex process 
involving very much advanced machinery and capital equipment 
and extensive infrastructure and controls. Equipment fab can 
cost tens of millions of dollars each, and there may be dozens 
or hundreds of these pieces of equipment in each facility.
 A leading edge facility can cost from $20 billion to $25 
billion for a single facility. This high level of investment 
and controls allow us to produce, at the molecular level, at 
the nanoscale, devices of ever-increasing performance and 
functionality.
 Our ability to operate and to innovate and manufacturer 
these devices and make these huge capital investments depends 
on advancements in engineering, material science, computer 
science, physics and chemistry.
 One part of the innovation framework entails the use of 
specialized chemicals that possess specific properties and 
characteristics and enable precision manufacturing. These 
chemicals work in conjunction with the advanced machinery in a 
highly controlled process.
 As a result, it is important for the U.S. semiconductor 
industry to have a well-functioning process for reviewing the 
chemicals that both protects the environment and allows our 
operations and innovation to go forward.
 The new chemicals we use are highly specialized to meet 
exacting performance requirements. Our use of these chemicals 
is characterized typically by very low volumes, by operations 
in closed systems and automated processes, and subject to 
extensive controls and engineering controls and other controls.
 As a result, fabs are among the most tightly controlled 
industrial environments on the planet. These conditions result 
in minimal risks to workers and the environment. We believe 
these factors should inform EPA's review of our use of new 
chemicals.
 The discussion draft under discussion is a positive step in 
the right direction, and we believe contains several elements 
that should inform future discussions, so that we can achieve 
bipartisan agreement on improvements to TSCA. The elements that 
we believe are most important, I think, are targeted reforms.
 First, we think it is important to assess the risks 
associated with the conditions of use and the unique conditions 
in the semiconductor industry that take into account the 
extensive levels of controls and the low volumes that we use.
 Second, we believe a narrow pathway to the use of low 
volume chemicals in tightly controlled environments and under 
specific conditions, such as those employed in the 
semiconductor industry, is appropriate.
 We also support the inclusion of defined timelines to 
ensure more predictability and certainty in the process. Then 
finally, we support ensuring that EPA has appropriate resources 
to implement its important mission and statutory requirements.
 We look forward to working with this committee and other 
stakeholders to achieve a bipartisan solution that both 
protects the environment and improves the review process, so 
that the U.S. semiconductor industry can continue to grow and 
innovate in the United States.
 Thank you.
 [The prepared statement of Mr. Isaacs follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] 
 
 Senator Ricketts. [Presiding.] I will take over as Chair 
while Senator Cramer is out. I will now welcome Dr. Michal 
Freedhoff. Welcome back to the committee. Thank you for being 
here.
 Dr. Freedhoff is a senior policy advisor at Holland and 
Knight. She previously served as the Assistant Administrator of 
the EPA Office of Chemical Safety and Pollution Prevention 
under the Biden administration, and played a key role in 
drafting and implementing the bipartisan 2016 Lautenberg 
amendments to TSCA, the last time Congress amended the program.
 Dr. Freedhoff, please proceed with your opening statement.

 STATEMENT OF MICHAL FREEDHOFF, PH.D., SENIOR POLICY ADVISOR, 
 HOLLAND AND KNIGHT, LLP

 Ms. Freedhoff. Chairman Ricketts, Senator Whitehouse, other 
members of the committee, thanks so much for the invitation to 
be here today.
 My name is Michal Freedhoff, and I am here in a personal 
capacity based on my prior work for Senator Markey and with 
other members of this committee on the 2016 TSCA amendments, 
and working as the Assistant Administrator of the EPA office 
that implements TSCA for the entirety of the Biden 
administration.
 I also want to make clear that while Holland and Knight 
represents clients related to TSCA fees authorization, I do 
not. My views today are my own, informed by my experience as 
the only person who both played a significant role in 
negotiating the 2016 law and lead its implementation at EPA.
 This committee played a central role in shaping the law 
that was almost unanimously enacted almost 10 years ago. We 
knew we were making foundational changes to the inadequate 1976 
law. We also knew that when the fees expired, Congress would 
need to reauthorize them. I am glad the committee has begun 
this important work.
 My written testimony describes four principles. First, 
safety and speed. That is what Congress wanted for new 
chemicals in 2016. I do not think Congress appreciated what it 
would take for EPA to review every new chemical in 2016. I also 
do not think that Congress knew that in between 1976 and 2016, 
80 percent of new chemicals went into commerce without a formal 
safety review. Sometimes that was because EPA was reasonably 
confident about the new chemical safety, but other times it was 
because the 90-day clock ran out before EPA could act.
 When I reflect on the decades of policy that led to 
Superfund sites, contaminated drinking water, cancer clusters 
caused by improper disposal of toxic chemicals, problems that 
came at an enormous cost, not just in dollars, but to people's 
lives, I can not help but reflect that if the 2016 new 
chemicals provisions had been there all along, we might have 
been able to ensure that the chemicals we rely on for our daily 
lives were safe before they got into our air, water, land and 
bodies.
 I do not believe that Congress should remove the 
requirement that EPA formally review new chemicals before they 
go into commerce. There are some provisions in the draft that 
result in that outcome. For example, there is language deeming 
some new chemicals to be equivalent to other chemicals that are 
already on the TSCA inventory, thus allowing EPA's review to be 
skipped altogether, even though most of the chemicals in the 
inventory have never been reviewed under TSCA.
 There are also provisions that could be read to mean that 
EPA might not be able to get information it needs to complete 
its review, if EPA was not already sure that the chemical was 
more likely than not to present an unreasonable risk.
 There are also things in the draft that could help, like 
reinvigorating the Sustainable Futures program, and the 
provisions that called for streamlined ways to review 
substantially similar chemicals would build on successful 
efforts that the first Trump and Biden administrations began.
 Second, TSCA fees were modeled after a similar periodically 
reauthorized pesticide fees program. Every single successful 
pesticide fees reauthorization has had the same unanimous 
support that the 2016 TSCA had. These fees provisions are not 
intended to force rewrites of the entire law, but rather to 
include only the things that everyone can agree to.
 Unfortunately, even with these, in almost 10 years, EPA has 
never had what it needed to meet deadlines for either existing 
or new chemicals.
 My third principle, ensuring EPA has the resources it needs 
to do the job, dovetails with the fourth, which is making sure 
any changes to the law are implementable.
 About 25 percent of EPA staff have left in the last year, 
including many of its most experienced leaders and a third of 
the lawyers who supported EPA's chemical safety efforts. The 
party of EPA that administers TSCA has about 40 fewer staff 
than the roughly 360 people it had at the end of the Biden 
administration.
 This draft mandates that EPA stand up new programs, 
functions, processes, rules, guidance documents, and other 
requirements generally in 1 year or less. Quite simply, this is 
not implementable and would likely slow things down, rather 
than speed them up.
 I believe it will benefit everyone for Congress to be as 
surgical as possible to ensure that any changes it makes not 
only preserve the protected policies in the 2016 law, but also 
do not unintentionally add to EPA's challenges of protecting 
people while meeting its deadlines.
 Thanks again for the invitation.
 [The prepared statement of Ms. Freedhoff follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] 
 
 Senator Curtis. [Presiding.] Thank you, Doctor.
 I would like to yield some time to myself for a few remarks 
and questions.
 Senator Whitehouse. Without objection.
 Senator Curtis. Okay.
 Senator Whitehouse. I just wanted to note that Senator 
Padilla will be taking my opening question spot. After you are 
concluded, Senator Curtis, Senator Padilla will be recognized.
 Senator Curtis. Okay. All right, thank you. I am grateful 
to our Chairperson, who is not here today, not feeling well, 
for this hearing. I am grateful to the Ranking Member. I have 
really been looking forward to this hearing to examine the 
regulatory environment for new and existing chemicals and its 
impact on innovation, safety, and American competitiveness.
 American companies invest billions of dollars each year to 
research and development to create materials that reduce 
emissions, improve safety, and strengthen our industrial base. 
When reviews under TSCA are delayed, unpredictable, or 
disconnected with real-world applications, innovation slows, 
research moves overseas, promising replacements are shelved, 
and American workers lose opportunities.
 There are few industries impacted more than semiconductors, 
which are critical to American and allied competitiveness. 
Advanced chips are developed on highly specialized chemicals 
that are essential to nearly every aspect of modern life. 
Interestingly, my wife and I lived in Taiwan in the 1980's. I 
saw first hand how strategic investment in semiconductors 
transformed its economy from producing Christmas lights to 
highly productive semiconductors. They have become a powerhouse 
because of that investment.
 One anecdote that stayed with me from our subcommittee 
hearing in October is that in some cases, aircraft are required 
to use an environmentally inferior chemical in the cargo hold 
even though a safer alternative has been approved for use in 
the passenger cabin of the same aircraft. That restriction 
stems from aviation safety, not from safety regulations, but 
from EPA's TSCA program. Even small formulation changes can 
trigger new reviews, delay safety, or more substantially 
alternate and disrupt supply chains.
 As we consider reauthorization, we should ensure the law 
allows manufacturers to build world-class products that meet 
the highest safety standards, while also providing certainty to 
companies that they can access the chemicals necessary to meet 
specifications or requirements.
 The question is not whether to regulate chemicals. Most 
recognize the value and importance of TSCA. The question is how 
we make these domestic chemicals manufacturing both predictable 
and safe.
 Dr. Engler, let me start with you. When EPA evaluates 
premanufacture notices, is it necessary to issue a significant 
new use rule for every new chemical? It seems we are 
effectively permitting an innovation and immediately regulating 
it in a way Congress did not intend.
 Also, when EPA does determine when a SNUR is appropriate, 
is there a more effective way to issue it so companies can 
bring their products to market without unnecessary delays?
 Mr. Engler. Senator, that is an excellent question. EPA has 
been issuing SNURs, orders and SNURs, some restriction on 85 to 
90 percent of new chemicals. It is not every new chemicals, 
again. If EPA finds it is low-low, EPA will let it go forward 
without a restriction.
 Many of the products that we have assisted clients bringing 
through the New Chemicals program, our view, and we have 
demonstrated to EPA mathematically, that it is extraordinarily 
unlikely that any release or exposure would exceed EPA's 
concern threshold, and yet EPA proceeds with the restriction.
 I think no, it is not necessary for EPA to take that level 
of restriction. That is what we have been seeing now across 
four different administrations.
 Senator Curtis. Thank you.
 Dr. Freedhoff, under the current framework, once a chemical 
is listed on the TSCA inventory, EPA's ability to ensure it is 
used only under the conditions described in the original 
submission is limited. As a result, EPA assesses, evaluates 
risk across a broad range of potential uses, making reviews 
more time consuming and resource intensive.
 The stewardship pathway takes a different approach. The 
chemical is authorized only for the specific conditions of use 
described in the submission. It is not added to the inventory 
and every entity in the supply chain is bound by an enforceable 
stewardship plan. Does this structure provide EPA assessors 
with a stronger basis to evaluate a chemical based on its 
intended use, knowing that use is legally constrained and 
enforceable? Would that improve predictability and the review 
process?
 Ms. Freedhoff. I appreciate the creativity of this idea, 
and I agree that by not listing the stewardship chemicals on 
the inventory, it ensures that EPA would have to review them 
later if someone else wanted to use the chemical for a 
different purpose.
 I still think that this pathway would be quite difficult 
for EPA to implement and would probably divert staff away from 
reviewing new chemicals while they figured out how to implement 
the program.
 Senator Curtis. Could we agree that it is a good 
conversation to have and that the creativity is----
 Ms. Freedhoff. I think that it is great to think of ways 
that EPA could protect people while meeting its deadlines.
 Senator Curtis. Thank you. I would love to further that 
conversation with you.
 Mr. Isaacs, have regulatory transitions affected your 
members' ability to develop and deploy new technologies and 
keep pace with semiconductor demand, especially as China 
continues to expand its capabilities?
 Mr. Isaacs. Yes, this is one factor that is very much a 
consideration in driving new investment. Our industry is very 
competitive and the United States is in a global race for 
attracting investments in our industry.
 Having more certainty and predictability with regard to 
being able to introduce new substances into the processes, 
particularly at the leading edge, the most advanced processes, 
is very important. That is why we think there should be 
targeted reforms to streamline the process and improve the 
process. We are not looking for open-ended exemptions, but 
rather reviews based on conditions of use that address the 
specific operating conditions in our industry.
 Senator Curtis. I would like to highlight two of the words 
you used there, consistency and predictability. It is not 
shortcuts, it is just like, what is the drill, and let us not 
change it. Let us be predictable and consistent.
 With that, I will come back to some more questions a little 
later. I will yield to the Senator from California.
 Senator Padilla. Thank you, Mr. Acting Chair. I think we 
both share the chair's interest in making TSCA work more 
efficiently.
 Mr. Isaacs, I am particularly interested in learning more 
about the semiconductor industry's perspective on TSCA. 
However, I must let it be known for the record that I cannot 
support the current draft of this legislation.
 I want to emphasize how much is at stake here. TSCA is 
critical to protecting the health of all Americans, including 
especially the more vulnerable populations, including the 
elderly, residents of frontline communities and others. Careful 
reviews of new chemicals by impartial EPA staff are essential 
in this effort.
 As a result, I do not see how we can undertake any TSCA 
reform effort unless we simultaneously restore EPA's staffing 
and expertise to levels that existed prior to 2024. It is just 
common sense. You can try to strike that right balance, Senator 
Curtis, but if you do not have the staff to do the work, then 
of course it is not going to get done on a timely basis.
 There are also other specific provisions of the bill that 
concern me. Unreviewed new chemicals should not be approved for 
use simply a critically understaffed EPA could not complete its 
analysis by a certain deadline. If you are fully staffed, then 
maybe the deadline can be more of a serious conversation and 
consideration.
 That is not the case. An artificial deadline, combined with 
understaffing, is allowed in several circumstances under this 
bill.
 I am also seriously concerned that the draft bill would 
prevent EPA from regulating a new chemical unless it is ``more 
likely than not to create an unreasonable risk of injury to 
public health or the environment.'' Now, that may sound 
innocuous to some, it may sound a little too vague for some.
 Let us drill down here. We are considering new chemicals 
that have no existing track record. Assembling enough evidence 
and data necessary to show that injury is more likely than not 
to occur could be very difficult as a result.
 This standard could also block EPA from regulating 
chemicals with significant risks. ``More likely than not'' is 
regularly understood to be a 51 percent chance or greater of 
something happening, right? A majority, more than 50 percent.
 This means that if EPA concludes that a new chemical has, 
say, only a 45 percent chance of causing significant cancer, 
let us say, to pregnant women, as an example, that the standard 
is not met and the EPA cannot regulate that chemical to try to 
reduce the potential cancer risk. That seems absurd to me.
 I know we want the certainty, we want the specifics. We 
always want the hard and fast number. The proper balance is 
going to include a little bit of flexibility, a little bit more 
context to make this important and critical determinations.
 That being said, let me pose a question to all of you. Do 
any of you believe EPA's hands should be tied in imposing 
restrictions on a new chemical? We can use that 45 percent 
example, just for conversation purposes, when a significant 
cancer risk for pregnant women or other vulnerable populations 
has been determined? We will start with Dr. Engler.
 Mr. Engler. The difference between not likely and more 
likely than not, this is a critical question that we do need to 
answer, I think, as a TSCA stakeholder community. Right now, 
the standard for EPA to proceed without a restriction is ``not 
likely.'' By your math, that would be 49 percent, or 51 
percent, it is that same line, it is below that line.
 That is not how EPA implements it. EPA, to not conclude 
that it may present, is looking for like 99 percent confidence 
that it is not going to happen and not likely is only like 1 
percent.
 I am not sure where that line is. I suggested more likely 
than not to help give EPA some direction about the uncertainty 
or the level of certainty that it needs to make that decision. 
I think that is one of the most important things that we need 
to discuss with this committee.
 Senator Padilla. Mr. Isaacs?
 Mr. Isaacs. Our main priority that whatever standard is 
used, and we support EPA undertaking a thorough and appropriate 
review of chemicals, that they do so looking at the conditions 
of use in our industry, the volumes, level of controls and 
such. We believe that their evaluation of risks under those 
circumstances will result in an appropriate determination.
 That is our highest concern with regard to the draft.
 Ms. Freedhoff. I think EPA should continue to be required 
to review the safety of new chemicals and to continue to have 
the authority to get the information it needs and impose the 
requirements if things are necessary.
 Senator Padilla. Thank you. Not to put words in your mouth, 
but ensuring that there is staffing capacity necessary to 
conduct those studies and reviews.
 Ms. Freedhoff. Their hands should not be tied.
 Senator Padilla. Yes. Thank you, Mr. Chair, and thank you, 
Ranking Member Whitehouse, for allowing me to ask questions.
 Senator Curtis. Senator Ricketts?
 Senator Ricketts. Thank you to all the witnesses for being 
here today and sharing your perspectives on the improvements as 
the committee works to reauthorize this important legislation. 
We all know that chemicals are essential for modern life. In 
agriculture, this includes chemicals used in crop protection 
tools, livestock production, and irrigation systems. These 
sectors are the economic backbone of my home State of Nebraska.
 As a matter of fact, Nebraska is a global leader in the 
production of irrigation systems. Vinyl chloride is a necessary 
chemistry for the irrigation tubing hoses and drip lines.
 In addition, chemicals and manufacturing inputs, like 
formaldehyde, also play a critical role in other key sectors. 
We just discussed the semiconductor industry.
 Over 500 chemicals go into making a single chip. Even 
though these chemistries are known to be safe, the TSCA review 
process has created more bottlenecks in the actual progress to 
compete across the world. Without reform, innovative 
chemistries that are safe for the environment are left in R&D 
pipelines instead of being used by industry and consumers. 
Frankly, this is kind of contrary to what we want. We want 
newer, safer chemicals rather than using the older ones that 
are not safe.
 This dynamic undermines, not advances, environmental 
progress, it dampens investment into the industry. Streamlining 
the approval process for chemistries that have already been 
verified represents meaningful process improvement reflected in 
the discussion draft. By creating a more efficient pathway for 
previously reviewed substances, the EPA can prioritize 
resources toward evaluating truly new chemistries.
 Getting the regulatory environment right is critical for 
food security, energy security and national security. We need 
to make sure that we are verifying these alternatives and move 
forward without unnecessary delay.
 Dr. Engler, Mr. Isaacs, how can we continue to strengthen 
and ensure industry continues to onshore chemical development 
in the U.S. rather than industry looking at countries overseas? 
Dr. Engler, we will start with you.
 Mr. Engler. Critical is predictable timelines. The CCI has 
not taken a formal position on 90-day review time. Maybe EPA 
needs more time. CCI has always felt that we do not want bad 
decisions faster.
 EPA absolutely needs the resources, they need the 
expertise, they need the independence. They need time to do the 
review. These reviews have been very unpredictable, both in 
terms of the timeline and in terms of the outcome. That has led 
to significant economic disruption for our members. They have, 
many of them have abandoned the U.S. 2016 Toxic Substances 
Control Act (TSCA) market and they register elsewhere in the 
world, Europe, Canada, Asia Pacific, with much more 
predictability. We are poorer for it, because those products 
are not available to our companies and to our consumers.
 Senator Ricketts. Mr. Isaacs, Dr. Engler talked about 
timelines. Do you have other things you think would help us 
onshore some of these industries?
 Mr. Engler. Yes. I think we need to take a holistic 
approach to a range of issues in terms of onshoring the 
semiconductor supply chain. I would add, chips are an 
increasingly important input into agricultural machinery used 
by farmers in your State and others. That includes everything 
from tax policy to work force policy and others.
 With regard to chemicals, I think having an appropriate 
level of review based on the controls employed and the real-
life conditions and risks at play, and certainty and 
predictability will result in a favorable outcome in terms of 
attracting new investment.
 Senator Ricketts. Ensuring the best available science 
serves as the foundation for TSCA reviews, the discussion draft 
includes a provision that would establish a robust peer review 
of risk evaluations. A true risk-based approach to reviewing 
and regulating chemicals is vital.
 Yet in the past, we have seen EPA ignore these how these 
chemicals are used in real-world industrial settings, such as, 
Mr. Isaacs, you were talking about, such as assuming non-
compliance with OSHA requirements. For example, EPA does not 
assume that workers are using PPE, even when mandated by OSHA. 
Additionally, EPA is establishing occupational exposure limits 
using methodologies that are inconsistent with current best 
practices. In some cases, this results in standards that are 
hundreds of times lower than the rest of the world.
 The discussion draft includes language on peer review, 
which is a good step toward increasing scientific rigor. Dr. 
Engler, would directing EPA to evaluate robust risk-based 
chemical reviews and adhere to clear scientific standards 
strengthen and clarify the existing TSCA framework?
 Mr. Engler. Yes, I think so. I think it would make it more 
predictable and more consistent. We would get less variability 
between and among assessors. Again, we would get more 
predictability in terms of outcome. It would be clearer to 
submitters what testing they need to do to inform EPA's risk 
assessment.
 Senator Ricketts. Great. Thank you very much. Thank you, 
Mr. Chairman.
 Senator Curtis. Thank you. I yield to the Ranking Member.
 Senator Whitehouse. Thank you very much, Chairman.
 Dr. Freedhoff, does it make sense to allow chemicals to 
avoid EPA review where there is equivalency to a chemical that 
has never been reviewed by EPA?
 Ms. Freedhoff. No.
 Senator Whitehouse. If you look at the change in the draft 
from the standard that the chemical may present unreasonable 
risk to a standard that it is more likely than not to present 
unreasonable risk, is there a danger that at that stage in the 
review proceeding there simply is not enough data yet to make 
that determination, and that therefore a chemical that may very 
well be more likely than not to present unreasonable risk will 
not meet that standard, simply because it is a sequencing 
problem, the question is being asked too early in the data-
gathering process?
 Ms. Freedhoff. I think that is a possibility, and I think 
it would be important to ask EPA, the career scientists, how 
they would implement that provision, should it be enacted.
 Senator Whitehouse. It would make sense to get rid of that 
potential anomaly, would it not?
 Ms. Freedhoff. Yes.
 Senator Whitehouse. Also, the discussion draft sets in 
review periods, they are placeholders at this stage, but 
whatever that number is for how long the review period lasts, 
would it be wise to make sure that the chemical industry is not 
in a position whereby simply delaying and prevaricating, it can 
run out the clock on EPA review and get an automatic approval 
because of its own non-compliance with requests for information 
or other participation in the review process?
 Ms. Freedhoff. I think any provision that lets chemicals go 
into commerce before EPA finishes its review takes us back to 
the 1976 TSCA and does not retain the provisions that are 
supposed to make sure the chemicals are safely made and used 
before they go into commerce.
 Senator Whitehouse. If we set up a process where the 
proponent of a chemical had the incentive to not comply with 
process, and run out the clock to an approval that was 
automated, basically, by the clock, that would be an 
unfortunate outcome and create potentially, it would 
incentivize some very bad behavior.
 Ms. Freedhoff. It could.
 Senator Whitehouse. You mentioned in your testimony that 
the scope and implementation requirements included in the draft 
would need to be simplified and narrowed in order to best set 
EPA up for success, a problem that is made worse by the subject 
of Senator Padilla's comments, that there simply is not 
adequate staff, that it has been cut back at EPA. When you 
burden a shrunk staff, you end up diminishing the authority and 
the scope and ability of EPA to move forward.
 You then go on to say that, ``we adopted policies and 
approaches,'' when you were at EPA, ``that greatly sped up the 
review of some types of new chemicals without sacrificing 
safety.'' You recommend that there is more along these lines 
that could be done.
 In my remaining minute, could you make some recommendations 
as to what more along these line could be done, and could you 
take the remainder of that question as a question for the 
record, so you can at appropriate length respond in writing to 
what more at length could be done.
 Ms. Freedhoff. Sure. During the Biden administration, we 
really prioritized getting the chemicals that the semiconductor 
sector needed into commerce more quickly. First we prioritized 
those chemistries for review, we had limited resources, we had 
to prioritize some things. We ended up reviewing semiconductor 
chemistries in about a third of the time as compared to the 
other length of reviews.
 We also really focused the agency's scientific energy on 
creating standardized and streamlined reviews for semiconductor 
chemistries. There are some types of semiconductor chemicals 
that are reviewed in under 90 days, still.
 I think there is more the agency can do that way. They 
could find science policies that let them not reinvent the 
wheel every single time a new chemical comes into the system, 
but draws on lessons learned from past reviews to help speed 
things up.
 Senator Whitehouse. Similarity, if not equivalency.
 Ms. Freedhoff. Yes.
 Senator Curtis. Yes. I yield to Senator Merkley.
 Senator Merkley. Thank you very much, Mr. Chairman, and 
thank you all. This is a very important topic.
 I would like to submit for the record an article entitled 
``She Fought for a Carcinogen, Now She's at the EPA Approving 
New Chemicals.''
 Senator Curtis. Without objection, so ordered.
 [The referenced information follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] 
 
 Senator Merkley. Thank you.
 This article notes that not only is the individual 
approving new chemicals a person who led an aggressive effort 
by industry to block regulations on formaldehyde, but another 
individual who was a former Chemistry Council leader is in 
charge of regulating existing chemicals.
 Start with concern that if the Chemistry Council has been 
put in charge of the process both for existing and new 
chemicals, I do not have a lot of confidence that true science 
is going to be honored. That is a concern.
 I want to start by noting that the existing draft says that 
third parties can be hired to do the approval process. Dr. 
Freedhoff, my concern is that those third parties might also 
not be entirely objective. Is that any concern that you might 
have?
 Ms. Freedhoff. I think what I would say is that EPA should 
be in charge of reviewing new chemicals. EPA should be in 
charge of reviewing existing chemicals. I think industry 
regularly gives the agency a lot of really valuable data and 
other information. It should be EPA that makes the decision 
about whether a chemical is safe.
 Senator Merkley. Thank you. That makes a lot of sense to 
me. Part of the reason I would argue for that position is that 
there is more oversight by Congress of what is going on inside 
EPA.
 Second, there is a low volume exemption. My team has filled 
me in that 600 PFAS chemicals were approved under low volume 
exemptions. That is a whole lot of PFAS with different 
chemistries being basically bypassed in the approval process 
completely. Given the known impacts of PFAS and how expensive 
it is to clean it up, does it makes sense to have a low volume 
exemption for tons of different varieties of PFAS?
 Ms. Freedhoff. During the Biden administration, we wrote a 
rule that made PFAS ineligible for low volume exemption, not 
because we did not think the semiconductor sector could safely 
use PFAS, but because we thought the complexity of the science 
associated with PFAS required a more robust review.
 I think when you have a chemistry that is complicated and 
chemicals that are persistent and bioaccumulative, those 
chemicals really do not lend themselves to a shorter review 
process, and really, those chemicals should go through the full 
review.
 Senator Merkley. My concern here is that with PFAS, we 
already knew a lot about its damage in the environment. 
Therefore, a rule like that made sense.
 The other new chemicals that are coming through the low 
volume exemption, we do not yet know what damage they are going 
to do. Is not it an open door to another kind of PFAS-style 
disaster?
 Ms. Freedhoff. I think it is safe to say the EPA should 
only proceed with low volume exemptions for chemistries that it 
confidently knows enough about to do that for. That is not 
every single chemistry.
 Senator Merkley. All right, thank you.
 My colleague noted the equivalency concern, that if 
equivalency is given a bypass because it is equivalent to a 
chemical that was never in the first place reviewed, you 
basically have an open door to unreviewed chemicals. Do I 
understand that correctly?
 Ms. Freedhoff. Yes, you do.
 Senator Merkley. One of the things that I am concerned 
about are the pyrolysis oils. Essentially, industry says, well, 
let us just melt down plastics. We know that a lot of fumes are 
generated that affect the health of surrounding communities, 
but that is a discussion for a different day.
 My concern here is that the argument put forward is that 
well, these melted down plastics resemble naphtha, and 
therefore we will just say, they do not have to be reviewed. 
Yet these melted down plastics contain an enormous number of 
additional ingredients, things that affect their stiffness, 
things that affect their clarity, their color, all sorts of 
different characteristics and different plastics.
 Does it make sense to have essentially melted down plastics 
bypassing the chemical review under an argument that they, 
well, look a little bit like naphtha?
 Ms. Freedhoff. Senator, I think I share your concerns 
completely. Not only has EPA known for years that there are 
some kinds of plastic feedstocks that release dioxins and other 
harmful chemicals. Additionally, I bet naphtha has never been 
reviewed under TSCA in the first place, like the tens of 
thousands of other chemicals that are on the TSCA inventory.
 I do not think the equivalency provisions ensure safety at 
all.
 Senator Merkley. Thank you very much. My time is expired, 
but those are some of the concerns that I feel are important as 
we look to revisions of TSCA before this committee.
 Senator Curtis. Thank you, Senator.
 I will now yield myself some time. It looks like I do not 
have a lot of competition for my additional questions.
 Senator Merkley. I yield as much time as you want.
 [Laughter.]
 Senator Curtis. Okay, good, thank you, Senator.
 I think if we were to try to summarize today's hearing into 
stereotypes, you would get the sense of, we have all of this 
innovation, we have all of these good things, we can not get 
them through this bottleneck. On the other side, if we do not 
do this safely, it is a problem.
 I do not think anybody here is suggesting we take 
shortcuts. We are all trying to just figure out how to make 
this more effective. I was very hard on the previous 
administration, for the record, of getting new chemicals 
through in the statutorily required time. When Lee Zeldin was 
here, I told him I would be equally hard on him if he was also 
unable to do this. It is a big problem.
 For the three of you, just for a moment, let us think about 
public safety, public health, but also innovation, the need to 
get these chemicals to market, to compete. What suggestions 
would all of you have specifically for Congress about how we 
may look at this and kind of bust through these stereotypes?
 Doctor, I will start with you. I would like to hear from 
all three of you.
 Ms. Freedhoff. Thanks very much for that. I think that 
everyone at EPA wants things to move more quickly, and they 
want things to move as protectively, without sacrificing the 
safety for speed. I do not think that changes from 
administration to administration.
 I do think focusing EPA on categories of types of 
chemicals, if you understand the hazard of the type of 
chemistry, then you do not need to do the hazard part of the 
risk assessment over and over and over again. You can move to 
kind of standardize the approach and greatly speed things up.
 I think some of the provisions in the draft bill that call 
on EPA to reestablish a program that used to really help 
industry understand what data EPA would find the most helpful 
and how EPA's models work would also really help with speed.
 The biggest thing I think Congress could do to help EPA 
speed things up is provide the resources sufficient to do the 
job. I honestly do not believe EPA has ever had enough to do 
it.
 Senator Curtis. I remember when I was critical in the 
previous administration and was pointed to, we do not have the 
employee, even though the dollars were appropriated. There has 
to be something we have to figure out. Even though Congress is 
giving the dollars, we are still not getting the resources to 
get it done. I would love to further that conversation.
 Mr. Isaacs?
 Mr. Isaacs. Senator, I agree with your summation of the 
hearing and am hopeful that there could be a bipartisan 
approach to thinking about improvements. We think the 
discussion draft has several concepts that it can be built 
upon.
 We are not looking for a circumvention of review. We are 
hopeful that EPA can make an appropriate risk determination 
based on the science, and do so expeditiously. We think that is 
not a tradeoff, but rather two complementary goals that can be 
achieved in conjunction with each other, if the assessment is 
targeted and based on real-life conditions of use and volumes 
and similar such factors.
 Senator Curtis. Thank you.
 Doctor?
 Mr. Engler. I agree with Dr. Freedhoff, the category 
approach is a very effective method. EPA has used it for 
decades. It was used prior to the Lautenberg amendments. It is 
being reestablished now, I do give credit for the Federal asset 
generator work that OPP has done, and OPPT is in the process of 
doing something similar for cathode materials for batteries, 
taking a very protective approach and applying it as these many 
novel cathode materials are coming in.
 It is a thorough review, and these things are being allowed 
to be marketed with significant restrictions. Yes, a category 
approach is a great way to go.
 I also want to agree, the Sustainable Futures was a very 
effective program to train people how EPA does its reviews. I 
think especially where EPA is now, with having lost the brain 
drain that they have suffered lately, Sustainable Futures can 
be used to train the next generation of employees that are 
brought on board.
 I think Sustainable Futures will help submitters, it will 
help EPA with training, and I think it will also provide 
transparency to the public on how EPA does its New Chemicals 
review. Those are all things that we see in the discussion 
draft.
 The other thing I want to mention is the Safer Choice 
Criteria. These are decades-old criteria for really outstanding 
ingredients for mostly cleaning products, but for consumer 
products. To meet those criteria, you need to have the data, 
you need to go to a third-party reviewer. EPA does have the 
final review, but these are third-party reviewers. Then they 
determine, or they tell EPA, this new chemical, this new 
ingredient does or does not meet the criteria.
 Having that, having the new chemicals meet that standard, 
get a preferential review in terms of timing, I think the EPA 
can be confident that those products are safe because it meets 
the Safer Choice standard. EPA still has the opportunity to 
review it. They are pre-established criteria.
 Senator Curtis. Thank you.
 I have a couple more questions, but I would like to yield 
to my colleague, Senator Alsobrooks. We are both trying to get 
over to vote. I will yield to you, then I will come back to 
finish up my questions.
 Senator Alsobrooks. Thank you so much. I want to say thank 
you as well to our witnesses for being here today.
 The 2016 Lautenberg amendments to the Toxic Substances 
Control Act were the product of years and years of bipartisan 
work by many people who were in this room today. I have heard 
from hundreds of my constituents who have urged me to protect 
the 2016 law. As our committee considers potential changes to 
that framework, our goal should be to improve efficiency 
without weakening the core public health protections that 
Congress put in place.
 Dr. Freedhoff, I have a question. In your written 
testimony, you stated that EPA has never had sufficient 
resources to meet TSCA's statutory deadlines, even before the 
recent 25 percent loss of staff. I wondered, if Congress 
imposes automatic approval timelines without addressing the 
staffing issue, what are the likely consequences?
 Ms. Freedhoff. Ultimately, EPA needs the resources to make 
sure not just that new chemicals are safe before they go into 
commerce, but also that the existing chemicals that are under 
review move forward under the program. There has not been a 
single proposed or final rule on existing chemicals that has 
come out in the last year. Those deadlines are being missed as 
well.
 Part of the reason for that is unquestionably the 
compounding loss of so many of the agency's top staff, and most 
experienced scientists, with the problem that the agency did 
not have enough resources to implement any part of the TSCA 
program before that happened.
 I think what you end up with is an erosion of safety and an 
erosion of public confidence in the safety of the chemicals 
that are needed for every part of our life.
 Senator Alsobrooks. The Trump administration's broad work 
force cuts, which you referenced some of here, and 
reorganizations have driven many senior career scientists and 
attorneys out of the EPA. A lot of them, of course, are my 
constituents. That office that administers TSCA has had about 
40 fewer staff than it had at the end of 2024.
 Do you think it is responsible for Congress to narrow 
safety reviews while the agency lacks experienced toxicologists 
and risk assessors?
 Ms. Freedhoff. I think Congress should help the agency do 
its job, and that means reviewing the safety of new and 
existing chemicals and not taking shortcuts on any part of the 
safety review.
 Senator Alsobrooks. Thank you. Dr. Freedhoff, I would like 
to ask you a couple of questions as well about Section 6 of the 
draft legislation proposing a third-party assessor program. The 
draft would direct EPA to set up a new program within 18 months 
to accredit third parties to review risk assessments for 
industry.
 Who at the EPA would be responsible for setting up this 
program?
 Ms. Freedhoff. It would be the same scientists and lawyers 
who are charged with reviewing the safety of new chemicals. 
They would be diverted from their work.
 Senator Alsobrooks. That is the question. If they spent 18 
months setting up the program, it presumably means that staff 
would be taking time away from these new chemicals that you are 
talking about?
 Ms. Freedhoff. I do think that is the case. Every time you 
tell the agency to set up a new process or program or rule or 
guidance document, it diverts staff away from their core 
mission. If there are so many fewer of them already, and they 
were struggling to meet their deadlines in the first place, 
some of this extra work, setting up new things, is going to 
make things even slower in the meantime.
 Senator Alsobrooks. You also referenced in your written 
testimony that there would be challenges with conflicts, or 
could be some challenges with conflicts of interest. I wonder, 
would you say a little more about the conflict of interest that 
you think might arise.
 Ms. Freedhoff. Sure. I think sometimes companies do their 
own chemical submissions and other times they hire other 
companies to do them. I just worry about a situation where a 
company that was in charge, that was hired to work on another 
company's submittal, was also deemed by EPA to be the third-
party assessors. They would sort of be grading their own work, 
in a way.
 It does feel like there is some potential for conflicts 
that would need to be managed if Congress moves forward with 
enacting this provision.
 Senator Alsobrooks. Just one other quick question, because 
I know we both have to go vote. I sit on the Health Committee, 
and the committee oversees the FDA. There is a program at the 
FDA known as GRAS, or Generally Recognized as Safe program. 
Under that program, companies can make an independent 
determination that a food additive is generally recognized as 
safe, and then use that additive in food consumed by Americans.
 Companies can notify FDA of this determination, but they 
are not required to do so. Many health advocates have 
criticized this program, and Section 6 of this chemical bill 
still seems to pave the way for the GRAS program, a GRAS-like 
program for TSCA.
 When so many people recognize the GRAS program is broken, 
why would we create a similar program for other chemicals?
 Ms. Freedhoff. I think people expect the Federal Government 
to keep harmful chemicals out of our air, water, food and 
consumer products. EPA's New Chemicals program and having EPA 
continue to be the decisionmakers in that program is an 
important part of that.
 Senator Alsobrooks. Thank you so much. I yield.
 Senator Curtis. Thank you, Senator. I will followup with 
just a couple quick questions.
 Section 21 of TSCA includes a process that allows members 
of the public to request certain chemical restrictions. When 
Congress overhauled the risk evaluation process in 2016, it 
failed to account for how the old Section 21 petition process 
would interact with EPA's review of high priority chemicals, 
the ones Congress intended the agency to consider first because 
of the elevated degree of risk.
 The law currently allows petitions to bypass the risk 
evaluation entirely, forcing the EPA toward restricting a 
chemical before the data needed to support that action has been 
deployed.
 Dr. Freedhoff, based on your experience in charge of the 
EPA's Chemical Safety office under the Biden administration, 
how does the existing Section 21 process expose the agency to 
legal vulnerabilities while also significantly diverting 
limited resources?
 Ms. Freedhoff. Thanks very much for that question.
 When I was at the agency, we did get some petitions for 
chemicals to go right to rulemaking without first doing the 
risk evaluation. What that meant was the agency could spend the 
time getting the information that would normally be part of a 
risk evaluation, so that it could write a legally and 
scientifically defensible rule, and they could not collect TSCA 
fees for that effort. Or the agency could deny the petition and 
risk being sued and having to go to court.
 In both cases, EPA had to divert experts away from the work 
that they were already struggling to complete in order to 
respond and implement any part of the petition process. In no 
case did a rule result in faster protections for people as a 
result of the petition process.
 I do think that it would help EPA conserve its resources if 
the petition part of TSCA was changed to better align with the 
TSCA prioritization and risk evaluation process.
 Senator Curtis. All right. I am going to ask just one more, 
so we have this question on the record.
 This is for Mr. Isaacs. The discussion draft recognizes 
EPA's current new chemical approval process is not designed to 
keep pace with the speed of innovation necessary to remain 
globally competitive in the semiconductor development, as the 
semiconductor industry is constantly making chips smaller, 
faster, and more powerful. The current new chemical process is 
simply not good enough.
 Several provisions in the draft, including the Stewardship 
Pathway and the Low Volume and Low Exposure authorizations, are 
designed to allow leading edge chemistries to be developed here 
in the United States for critical industries like semiconductor 
development.
 Mr. Isaacs, will you please identify the key provisions of 
this discussion draft that would improve the chemical approval 
process for your members? I am going to ask you to be really 
brief, and perhaps we could have you even submit an answer for 
the record.
 Mr. Isaacs. Yes, thank you, we would be happy to.
 I should clarify that typically, it is not our industry 
that secures the chemical approval, but it is our chemical 
suppliers who are key partners in our innovation.
 The key provisions that I spoke to earlier, I think, are 
No. 1, a focus on the conditions of use as the guideposts for 
the risk assessment. No. 2, a pathway for low volumes that 
allows EPA to make certain determinations, taking into account 
those low volumes and the controls that are in place. No. 3, 
some sort of defined timelines to provide certainty and 
predictability in the process. Finally, as has been discussed, 
providing EPA with sufficient resources to implement the 
program.
 Senator Curtis. Thank you.
 We are going to yield to the Senator from Massachusetts, 
and see if we can get you in and get over to the vote as well, 
Senator.
 Senator Markey. Great, thank you, Mr. Chairman.
 First of all, thank you, Dr. Freedhoff, for your decades of 
work, including 16 years in my office on protecting the public 
from dangerous chemicals.
 As you know, one of my first battles in Congress was to 
bring justice to families in Woburn, Massachusetts, who were 
harmed by a chemical called Trichloroethylene (TCE). Their 
exposure to TCE, children fell sick with leukemia, and died 
deaths that may have been prevented if we had laws in place 
that allowed us to ban the use of these chemicals to begin 
with. It did not exist at that time.
 That was Woburn, Massachusetts, it became one of the 
principal sites that led to the creation of the Superfund 
program.
 The bipartisan 2016 TSCA amendments gave us the tools to 
finally ban TCE, which Dr. Freedhoff did in part, as part of 
the Biden administration in 2024. Unfortunately, the Trump EPA 
delayed the ban last year.
 For all the families that are worried about whether 
dangerous chemicals will hurt their health and their kids, we 
need a TSCA with teeth. This discussion draft would de-fang 
TSCA.
 When I helped craft the fee authorization 10 years ago, the 
intent was not to require us to reopen the entire statute 10 
years later, just to renew the EPA's ability to issue fees. We 
do not need to hammer at TSCA's foundation by weakening safety 
standards, creating new loopholes to exempt chemicals from 
review or allow industry to call the shots on scientific 
standards.
 The Trump administration is already working to undermine 
TSCA without any legislative changes. In just over a year, 
President Trump has fired EPA scientists and regulatory experts 
that together held hundreds of years of knowledge and 
experience, losing from one out of every four EPA employees.
 Dr. Freedhoff, has the Trump administration taken any real 
action on existing chemicals in the past year?
 Ms. Freedhoff. No. There has not been a single proposed or 
final rule for an existing chemical under TSCA in the last 
year.
 Senator Markey. They did say that formaldehyde does not 
cause cancer.
 Ms. Freedhoff. They did. They have finished some risk 
evaluations. They reviewed the formaldehyde risk evaluation. It 
is important to note that risk evaluation completion is 
actually under a court-ordered consent decree. For all of the 
other work, the rules that the Biden administration proposed 
but did not finalize, those remain unfinalized. Rules for risk 
evaluations that were finished by the Biden administration have 
not been proposed.
 Senator Markey. To put it bluntly, would this draft 
legislation make it easier or harder for EPA to get dangerous 
existing chemicals off the market?
 Ms. Freedhoff. I think ultimately this draft would divert 
agency resources away from its new and existing chemicals work, 
and that would ultimately make it harder for EPA to continue 
with ongoing efforts.
 Senator Markey. The EPA can not fulfill its mission to 
protect human health and the environment when its core 
scientific arms have been sacrificed on the altar of Elon Musk 
and DOGE. This bill would not fix what is broken; it would 
break TSCA further and let more potentially dangerous chemicals 
sneak through the cracks.
 This bill would only allow EPA to review a chemical's uses 
that are identified by the manufacturer, preventing EPA from 
doing its own assessment of all the ways a chemical could 
reasonably be used.
 Dr. Freedhoff, would limiting the EPA's review of 
reasonably foreseeable uses potentially expose more Americans 
to harm?
 Ms. Freedhoff. It is certainly possible. If only, if the 
way that the original company wants to use the chemical is 
safe, that is great. If other companies come in and then use 
the very same chemical to do other things, but EPA has not 
reviewed those other things, that could lead to public health 
harm.
 Senator Markey. One of the comments I use is, if students 
could have take-home exams and then give themselves a grade, 
there would be a lot of A-pluses that they would give 
themselves. We just can not let the manufacturers have a take-
home exam that they grade. We need to have a way of looking at 
this that is objective and dispassionate.
 From my perspective, EPA does not have the power to police 
how every individual customer might use a chemical once it is 
on the market. EPA should have the power to prevent people from 
being hurt by chemicals on the market. That is what we would 
lose to this change. This bill does not just mean fewer 
chemicals would get reviewed, it also means that the reviews 
that would have been would not actually keep people safe.
 Chemical companies are responsible to their shareholders, 
not to the American public. These companies fight lawsuits, 
while American families fight cancer. That is why EPA and TSCA 
exist, so that someone is responsible for the health and well-
being of the American public.
 If chemical companies get to set the rules of engagement, 
EPA might as well walk off the field. That is where we were in 
1979 and 1980, in Woburn, Massachusetts. I brought the EPA in, 
I brought the investigators in, it eventually became a book 
called A Civil Action, and it eventually became a movie called 
A Civil Action that Robert Redford produced and John Travolta 
played the lawyer.
 It was only to combat these companies that were going to 
sue all the way. They were not going to admit the harm that 
their chemicals did, TCE. What we had was unfortunately too 
many children in Woburn died from leukemia because of that 
substance in the waters.
 We just have to avoid repeating the past. I thank you, Mr. 
Chairman, for your indulgence.
 Senator Curtis. Thank you, and I would like to point out 
that many of these chemicals that are in the backlog would 
replace dangerous chemicals. That is the other side of this 
coin, to your point, Senator. If we want to replace these 
chemicals, we have quite a host of chemicals that are safer and 
cleaner for our environment that we need to get through the 
system.
 With no further questions, I would like to thank the 
witnesses. You have been great today. All my colleagues for 
your participation in today's hearing.
 Senators who wish to submit written questions for the 
record have until 5 p.m. on Wednesday, March 18th to do so. The 
witnesses' responses to those questions are due back to the 
committee no later than 5 p.m. on Wednesday, April 1st, and 
will be submitted for the record.
 With that, the hearing is adjourned. Thank you very much.
 [Whereupon, at 11:29 a.m., the hearing was adjourned.]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] 
 
 [all]